Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (10256)	2/17/2009 5:16:15 AM
From: idos	1 Recommendation Read Replies (1) \| Respond to of 10280

Exactly when it was expected as W-H exclusivity expired mid Dec. Patents are running till Aug 2012 but SEPR is after extension carrying into 2014 and if pediatric trials succceed, another 6 months. Lunesta is an enantiomer of previously known compounds (the S-isomer of racemic zopiclone). Now about the isomer use patent covering Lunesta, it depends how broadly courts interpret KSR especially for enantiomers but the isomer's benefit is unexpected and may not be considered obvious.